Grade A · clinically studied1 peptide · 7 studies
GLP-1 Blends
Stimulates GLP-1 secretion | Appetite regulation
This is a description, not a protocol to follow
Everything below is a summary of what people report doing and what the literature contains. Nothing here is medical advice.
What the evidence actually supports
Supported in animals
Animal-model studies indexed · 0
Cell and in-vitro studies indexed · 2
Reviews and uncategorised studies · 4
Not established
Any effect in humans · 1 human study indexed
Human dose, route or duration · no PK study indexed
Protocol details
The indexed studies did not investigate GLP-1 Blends as a combination of compounds. Instead, they focused on various aspects related to GLP-1 and its potential applications. For instance, one study reviewed the importance of dietary fiber for pediatric gastrointestinal health, noting that a significant percentage of children do not meet recommended fiber intake levels, which can lead to health risks [1].
Another study examined the clinical translatability of caprate-based tablet formulations for gastric peptide delivery, reporting a 57% increase in peptide exposure in dogs compared to a benchmark formulation. However, this benefit was not observed in humans, highlighting the limitations of translating animal study results to clinical practice [2].
In addition, research on algal-derived peptides suggested potential health benefits, although the evidence from human trials was limited and indicated only modest improvements [3]. Other studies explored the effects of different protein sources on metabolism and appetite, but these did not specifically address GLP-1 Blends [4].
Furthermore, in vitro assessments indicated that certain essential amino acid blends might promote GLP-1 secretion, but these findings require further investigation in human studies to determine their relevance [6]. Lastly, a study found that specific extracts could stimulate GLP-1 secretion in a cell line, but the clinical significance of this effect remains uncertain [7]. Overall, the evidence does not support the study of GLP-1 Blends as a combination of compounds.
Sources
[1] Dietary fiber in pediatric gastrointestinal health: a narrative review of evidence and challenges. — 2026 https://doi.org/10.3345/cep.2026.00276
[2] An effort to enhance the clinical translatability of caprate-based tablet formulations in gastric peptide delivery. — 2026 https://doi.org/10.1007/s13346-025-01978-7
[3] Navigating the potential of algal peptides: health effects, market applications, and scientific challenges. — 2026 https://doi.org/10.1080/07853890.2026.2637282
[4] The Acute Effect of Consuming Whey Versus a Plant-Based Protein Blend on Postprandial Metabolism and Appetite in a Sample of Healthy Adults. — 2026 https://pubmed.ncbi.nlm.nih.gov/41695112/
[6] In Vitro Assessment of the Bioaccessibility and Hypoglycemic Properties of Essential Amino Acids Blend: Implication for Diabetes Management. — 2025 https://pubmed.ncbi.nlm.nih.gov/40871634/
[7] Combination of Citrus aurantifolia Fruit Rind and Theobroma cacao Seed Extracts Stimulates Glucagon-Like Peptide-1 Secretion by Activating hTAS2Rs and the Phospholipase C-Mediated Signaling Pathway in NCI-H716 Cells. — 2025 https://pubmed.ncbi.nlm.nih.gov/41180086/
Research & studies for this protocol
7 rows · showing 7Newest first
| Study | Compound | Source | Year |
|---|---|---|---|
| This narrative review discusses the role of dietary fiber in pediatric gastrointestinal health, highlighting the inadequate intake levels among children. It emphasizes the association between low fiber consumption and gastrointestinal issues, particularly functional constipation, which affects a significant percentage of children globally. No specific treatment claims are made. | GLP-1 Blends | europepmc | 2026 |
| This study evaluated a sodium caprate (C10)-based tablet formulation with meglumine as a pH modifier for gastric peptide delivery. It was tested in dogs and humans, with a focus on bioavailability. The formulation showed a 57% increase in exposure in dogs compared to a sodium salcaprozate (SNAC)-based formulation. | GLP-1 Blends | europepmc | 2026 |
| This review evaluates the health effects and market applications of algal-derived peptides, focusing on their nutritional content and mechanistic actions. Limited human trials suggest modest improvements in various health metrics. The study highlights the need for standardized production and robust clinical evidence. | GLP-1 Blends | europepmc | 2026 |
| This study measured the acute effects of whey protein versus a plant-based protein blend on postprandial metabolism and appetite in 15 healthy adults. Participants consumed 20 g of protein from either source, and various metabolic markers were assessed over 3 hours. Results indicated comparable metabolic effects between whey and the plant protein blend. | GLP-1 Blends | PubMed | 2026 |
| Not reported in abstract. | GLP-1 Blends | SemanticScholar | 2010 |
| This study assessed the bioaccessibility and hypoglycemic properties of a blend of essential amino acids (EAA) called GAF in vitro. The research involved evaluating its DPP-IV inhibitory properties and its effect on GLP-1 secretion in cellular models. No therapeutic claims are made. | GLP-1 Blends | PubMed | 2025 |
| This study evaluated the effects of LN19183, a proprietary blend of Citrus aurantifolia fruit rind and Theobroma cacao seed extracts, on glucagon-like peptide-1 (GLP-1) secretion in the NCI-H716 cell line. The blend was administered at a dose of 50 µg/mL, resulting in a statistically significant increase in GLP-1 secretion. The study also explored the underlying signaling mechanisms involved in this process. | GLP-1 Blends | PubMed | 2025 |